Summary

North America Graft-Versus-Host Disease (GVHD) Treatment Market is expected to reach USD 3.44 billion by 2032, from USD 2.30 billion in 2024 growing at the CAGR of 5.3% in the forecast period of 2025 to 2032.
Market Segmentation:
North America Graft-Versus-Host Disease (GVHD) Treatment Market, By Treatment (Medication and Therapy), Type (Chronic GVHD, Acute GVHD, and Prophylactic), Gender (Female and Male), Age (Adults and Pediatric), Method of Administration (Oral, Intravenous, Topical, and Others), End User (Hospitals, Transplant Centers, Institutes, and Specialty Centers), Distribution Channel (Direct Tender, Retail Sales, and Others), By Country (U.S., Canada, and Mexico) – Industry Trends and Forecast to 2032
Overview of North America Graft-Versus-Host Disease (GVHD) Treatment Market Dynamics:

Driver
• Increasing Incidence of Hematopoietic Stem Cell Transplants (HSCT)

Restrain
• High Cost of Medications and Supportive Care

Opportunity
• Market Expansion through Strategic Initiatives and Partnership
Market Players

The key market players for North America graft-versus-host disease (GVHD) treatment market are listed below:

• Bristol-Myers Squibb Company
• AbbVie Inc
• Novartis AG
• Janssen Global Services, LLC
• Mallinckrodt
• Incyte
• Sanofi
• Alkem Laboratories Ltd
• Astellas Pharma Inc.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF THE NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET 20
1.4 CURRENCY AND PRICING 22
1.5 LIMITATIONS 22
1.6 MARKETS COVERED 22
2 MARKET SEGMENTATION 26
2.1 MARKETS COVERED 26
2.2 GEOGRAPHICAL SCOPE 27
2.3 YEARS CONSIDERED FOR THE STUDY 28
2.4 DBMR TRIPOD DATA VALIDATION MODEL 29
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
2.6 MULTIVARIATE MODELLING 33
2.7 MARKET END USER COVERAGE GRID 34
2.8 DBMR MARKET POSITION GRID 35
2.9 VENDOR SHARE ANALYSIS 36
2.10 SECONDARY SOURCES 37
2.11 ASSUMPTIONS 37
3 EXECUTIVE SUMMARY 38
4 PREMIUM INSIGHTS 41
4.1 PESTAL ANALYSIS 45
4.2 PORTERS FIVE FORCES ANALYSIS 46
5 REGULATORY FRAMEWORK 47
6 MARKET OVERVIEW 52
6.1 DRIVERS 54
6.1.1 INCREASING INCIDENCE OF HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT) 54
6.1.2 RISING AWARENESS CAMPAIGNS AND PATIENT EDUCATION 55
6.1.3 ADVANCEMENTS IN TREATMENT OPTIONS FOR GRAFT-VERSUS-HOST DISEASE (GVHD) 56
6.2 RESTRAINTS 57
6.2.1 HIGH COST OF MEDICATIONS AND SUPPORTIVE CARE 57
6.2.2 DISEASE HETEROGENEITY IN GRAFT-VERSUS-HOST DISEASE (GVHD) IMPLICATIONS FOR TREATMENT AND CLINICAL TRIALS 58
6.3 OPPORTUNITIES 59
6.3.1 MARKET EXPANSION THROUGH STRATEGIC INITIATIVES AND PARTNERSHIP 59
6.3.2 GROWING PIPELINE OF INNOVATIVE DRUGS FOR GVHD TREATMENT 60
6.3.3 EMPOWERING PATIENT-CENTRIC APPROACH TO GVHD TREATMENT 61
6.4 CHALLENGES 62
6.4.1 STRINGENT REGULATIONS IN GVHD THERAPIES 62
6.4.2 SAFETY CONCERN AND COMPLEXITIES DURING TREATMENT 62
7 NORTH AMERICA GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET, BY TYPE 64
7.1 OVERVIEW 65
7.2 CHRONIC GVHD 68
7.2.1 CORTICOSTEROIDS 69
7.2.1.1 PREDNISOLONE 70
7.2.1.2 METHYLPREDNISOLONE 70
7.2.2 IMMUNOSUPPRESSIVE 70
7.2.2.1 MYCOPHENOLATE MOFETIL (MMF) 70
7.2.2.2 METHOTREXATE (MTX) 70
7.2.2.3 ANTITHYMOCYTE GLOBULIN (ATG) 71
7.2.2.4 OTHERS 71
7.2.3 CALCINEURIN INHIBITORS 71
7.2.4 OTHERS 71
7.2.5 BRANDED 72
7.2.5.1 REZUROCK 72
7.2.5.2 IMBRUVICA 72
7.2.5.3 JAKAFI 72
7.2.6 GENERIC 72
7.3 ACUTE GVHD 73
7.3.1 CORTICOSTEROIDS 74
7.3.1.1 METHYLPREDNISOLONE 75
7.3.1.2 PREDNISOLONE 75
7.3.2 IMMUNOSUPPRESSIVE 75
7.3.2.1 MYCOPHENOLATE MOFETIL (MMF) 75
7.3.2.2 RUXOLITINIB 75
7.3.2.3 OTHERS 76
7.3.3 CALCINEURIN INHIBITORS 76
7.3.3.1 TACROLIMUS (TAC) 76
7.3.3.2 CYCLOSPORIN (CSA) 76
7.3.4 OTHERS 76
7.4 PROPHYLACTIC 77
7.4.1 CYCLOSPORIN (CSA) 78
7.4.2 METHOTREXATE (MTX) 78
7.4.3 TACROLIMUS (TAC) 78
7.4.4 METHYLPREDNISOLONE 78
7.4.5 OTHERS 79
7.4.6 GENERIC 79
7.4.7 BRANDED 79
8 NORTH AMERICA GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY AGE 80
8.1 OVERVIEW 81
8.2 ADULTS 84
8.3 PEDIATRIC 85
9 NORTH AMERICA GRAFT-VERSUS-HOST- DISEASE (GVHD) TREATMENT MARKET, BY GENDER 86
9.1 OVERVIEW 87
9.2 FEMALE 90
9.3 MALE 91
10 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY METHOD OF ADMINISTRATION 92
10.1 OVERVIEW 93
10.2 ORAL 96
10.3 INTRAVENOUS 97
10.4 TOPICAL 98
10.5 OTHERS 99
11 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY TREATMENT 100
11.1 OVERVIEW 101
11.2 MEDICATION 104
11.2.1 CORTICOSTEROIDS 105
11.2.1.1 METHYLPREDNISOLONE 105
11.2.1.2 PREDNISOLONE 106
11.2.2 IMMUNOSUPPRESSIVE 106
11.2.2.1 MYCOPHENOLATE MOFETIL (MMF) 106
11.2.2.2 METHOTREXATE (MTX) 106
11.2.2.3 ANTITHYMOCYTE GLOBULIN (ATG) 106
11.2.2.4 OTHERS 107
11.2.3 CALCINEURIN INHIBITORS 107
11.2.3.1 TACROLIMUS (TAC) 107
11.2.3.2 CYCLOSPORIN (CSA) 107
11.2.3.3 OTHERS 107
11.2.4 BRANDED 108
11.2.4.1 REZUROCK 109
11.2.4.2 IMBRUVICA 109
11.2.4.3 JAKAFI 109
11.2.4.4 ORENCIA 109
11.2.4.5 OTHERS 109
11.2.5 GENERIC 109
11.3 THERAPY 110
12 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY END USER 111
12.1 OVERVIEW 112
12.2 HOSPITALS 115
12.2.1 PUBLIC 116
12.2.2 PRIVATE 116
12.3 TRANSPLANT CENTERS 117
12.4 INSTITUTES 118
12.5 SPECIALITY CENTERS 119
13 NORTH AMERICA GRAFT-VERSUS-HOST-DISEASE (GVHD) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 120
13.1 OVERVIEW 121
13.2 DIRECT TENDER 124
13.3 RETAIL SALES 125
13.3.1 HOSPITAL PHARMACY 126
13.3.2 RETAIL PHARMACY 126
13.3.3 ONLINE PHARMACY 126
13.4 OTHERS 127
14 NORTH AMERICA GRAFT-VERSUS-HOST DISEASE (GVHD) TREATMENT MARKET, BY REGION 128
14.1 NORTH AMERICA 131
14.1.1 U.S. 142
14.1.2 CANADA 154
14.1.3 MEXICO 164
15 NORTH AMERICA GRAFT VERSUS HOST DISEASE (GVHD) TREATMENT MARKET: COMPANY LANDSCAPE 173
15.1 COMPANY SHARE ANALYSIS: GLOBAL 173
16 SWOT ANALYSIS 174
17 COMPANY PROFILE 175
17.1 BRISTOL-MYERS SQUIBB COMPANY 175
17.1.1 COMPANY SNAPSHOT 175
17.1.2 REVENUE ANALYSIS 176
17.1.3 COMPANY SHARE ANALYSIS 176
17.1.4 PRODUCT PORTFOLIO 177
17.1.5 RECENT DEVELOPMENTS 178
17.2 ABBVIE INC. 179
17.2.1 COMPANY SNAPSHOT 179
17.2.2 REVENUE ANALYSIS 180
17.2.3 COMPANY SHARE ANALYSIS 180
17.2.4 PRODUCT PORTFOLIO 181
17.2.5 RECENT DEVELOPMENTS 181
17.3 JANSSEN NORTH AMERICA SERVICES, LLC 183
17.3.1 COMPANY SNAPSHOT 183
17.3.2 REVENUE ANALYSIS 183
17.3.3 COMPANY SHARE ANALYSIS 184
17.3.4 PRODUCT PORTFOLIO 184
17.3.5 RECENT DEVELOPMENTS 184
17.4 SANOFI 186
17.4.1 COMPANY SNAPSHOT 186
17.4.2 REVENUE ANALYSIS 186
17.4.3 COMPANY SHARE ANALYSIS 187
17.4.4 PRODUCT PORTFOLIO 187
17.4.5 RECENT DEVELOPMENTS/NEWS 187
17.5 INCYTE 189
17.5.1 COMPANY SNAPSHOT 189
17.5.2 REVENUE ANALYSIS 189
17.5.3 COMPANY SHARE ANALYSIS 190
17.5.4 PRODUCT PORTFOLIO 190
17.5.5 RECENT DEVELOPMENTS 191
17.6 ALKEM LABORATORIES LTD. 192
17.6.1 COMPANY SNAPSHOT 192
17.6.2 REVENUE ANALYSIS 193
17.6.3 PRODUCT PORTFOLIO 193
17.6.4 RECENT DEVELOPMENT 193
17.7 ASTELLAS PHARMA INC. 194
17.7.1 COMPANY SNAPSHOT 194
17.7.2 REVENUE ANALYSIS 194
17.7.3 PRODUCT PORTFOLIO 195
17.7.4 RECENT DEVELOPMENT 195
17.8 MALLINCKRODT 196
17.8.1 COMPANY SNAPSHOT 196
17.8.2 REVENUE ANALYSIS 196
17.8.3 PRODUCT PORTFOLIO 197
17.8.4 RECENT DEVELOPMENTS/NEWS 198
17.9 NOVARTIS AG 199
17.9.1 COMPANY SNAPSHOT 199
17.9.2 REVENUE ANALYSIS 199
17.9.3 PRODUCT PORTFOLIO 200
17.9.4 RECENT DEVELOPMENTS 200
18 QUESTIONNAIRE 202
19 RELATED REPORTS 205